Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | CHKA | P35790 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283317 | 0.92 | ALDH1A1 (0.76) | ALDH1A1STAT6SMN1; SMN2SIGMAR1KDM4E | |
| SCHEMBL10283316 | 0.85 | — | — | |
| SCHEMBL10246596 | 0.82 | SIGMAR1 (0.47) | ALDH1A1STAT6SMN1; SMN2SIGMAR1CHKA | |
| SCHEMBL10283309 | 0.80 | — | — | |
| SCHEMBL10283311 | 0.80 | — | — | |
| SCHEMBL2554621 | 0.78 | ALDH1A1 (0.75) | ALDH1A1STAT6SMN1; SMN2POLBTDP1 | |
| SCHEMBL10283324 | 0.78 | ALDH1A1 (0.75) | ALDH1A1STAT6SMN1; SMN2POLBTDP1 | |
| SCHEMBL771676 | 0.76 | CHKA (0.47) | ALDH1A1SIGMAR1CHKACA2NCF1 | |
| Potassium Ion SCHEMBL604175 | 0.74 | SIGMAR1 (0.42) | ALDH1A1STAT6SMN1; SMN2SIGMAR1CHKA | |
| SCHEMBL12605217 | 0.73 | SIGMAR1 (0.56) | ALDH1A1SIGMAR1CHKACA2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041193-A1 | SUBSTITUTED INTERNAL VINYL-BORONIC ACIDS AND BORONIC ACID DERIVATIVES | FRONTIER SCIENTIFIC, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041193-A1 | SUBSTITUTED INTERNAL VINYL-BORONIC ACIDS AND BORONIC ACID DERIVATIVES | FRONTIER SCIENTIFIC, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041193-A1 | SUBSTITUTED INTERNAL VINYL-BORONIC ACIDS AND BORONIC ACID DERIVATIVES | FRONTIER SCIENTIFIC, INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041193-A1 | SUBSTITUTED INTERNAL VINYL-BORONIC ACIDS AND BORONIC ACID DERIVATIVES | BLVRB, BTD, BCL6B | ALDH1A1 3325/4885STAT6 3176/4885SMN1; SMN2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.